Thrombotargets approach to discovery and development enables drug candidates to rapidly advance through all clinical phases, therefore increasing the chances of a successful treatment that could reach the patients sooner.
Thrombotargets is an innovative drug discovery and drug development group of biotech companies developing new medicines based on the advances in recombinant DNA, molecular biology and small molecule drug technologies. Thrombotargets programs leverage the company haemostasis expertise and are focused on inherited and acquired Hemorrhagic and Thrombotic disorders.
Thrombotargets has developed and adapted to High Throughput Screening a new family of biological assays capable to simultaneously quantify clot formation and clot lysis (HemostaBioplatformScreen), total antioxidant capacity (OxidantBioplatformScreen) and low-density lipoprotein modification (AtheroBioplatformScreen). With these proven proprietary new HTS Platforms named BioPlatformScreen™, Thrombotargets group is creating continuously creating a novel and promising pipeline of drug candidates. Currently, two of Thrombotargets most innovative drug candidates are undergoing Preclinical trials. TT-173 program will start Phase I clinical trials Q2 2010
Accomplishments
-
Beginning of the preclinical studies with proprietary drug candidates.
-
Discovery and development of a robust pipeline of proprietary leads.
-
Building of fully integrated thrombosis and haemostasis drug discovery capabilities.
-
Alliances establishment with several Compounds Screening owners to access to Thrombotargets´ screening technology platforms.
-
Development of the High Throughput Screening Pathway Activity, named BioplatformScreenTM.
-
New High Throughput Screening Pathway Activity (HTS-PA) family raise, Hemosta-BioplatformScreenTM, OxidantBioplatformScreenTM and AtheroBioplatformScreenTM.
- Orphan Drug Designation for the procoagulant agent TT-103MH in the treatment of bleeding episodes in haemophiliacs and von Willebrand patients.